Pemetrexed Disodium Heptahydrate
Product Description
Dr Reddys Laboratories Ltd
-
Country/Region:India
-
On CPHI since:2019
Specifications
Dr Reddys Laboratories Ltd
-
Country/Region:India
-
On CPHI since:2019
More Products from Dr Reddys Laboratories Ltd (99)
-
Product Ondansetron Base
A selective 5-HT3 receptor antagonist API used as an antiemetic. -
Product Ondansetron Hydrochloride
A selective 5-HT3 receptor antagonist API used as an antiemetic. -
Product Palbociclib
A CDK4 and CDK6 inhibitor API used in hormone receptor positive breast cancer. -
Product Palonosetron Hydrochloride
A second generation 5-HT3 receptor antagonist API used to prevent nausea and vomiting. -
Product Pantoprazole Sodium
A proton pump inhibitor API used for acid related gastrointestinal disorders. -
Product Pazopanib
A multikinase angiogenesis inhibitor API used in renal cell carcinoma and soft tissue sarcoma. -
Product Permethrin
A synthetic pyrethroid API used as a topical antiparasitic agent. -
Product Pioglitazone Hydrochloride
A thiazolidinedione PPAR gamma agonist API used for type 2 diabetes. -
Product Pomalidomide
An immunomodulatory antineoplastic API used in multiple myeloma. -
Product Posaconazole
A triazole antifungal API used for prevention and treatment of invasive fungal infections. -
Product Pregabalin
A gabapentinoid API used for neuropathic pain, epilepsy and fibromyalgia. -
Product Quetiapine Fumarate
An atypical antipsychotic API used for schizophrenia, bipolar disorder and depression adjunct therapy.
Dr Reddys Laboratories Ltd resources (5)
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic and Wegovy, addressing the growing demand for accessible treatments in India.
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 1
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force?
-
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.
-
News Aurigene Pharmaceutical Services to expand biologics CDMO capacity with a new biomanufacturing facility
Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors. -
News CPHI Podcast Series: The importance of Pharma 4.0 to innovation leads in India
In this latest episode from the CPHI Podcast Series, Digital Editor Lucy Chard speaks to Sanjay Sharma, Global Head of Manufacturing, from Dr Reddy’s. Sanjay has over 26 years of experience in roles encompassing sales, the supply chain, and technical operations.
